Genetic Testing—Access and Diagnosis, and Direct-to-Consumer vs. Clinical Testing

Magellan Healthcare webinar, “Genetic Testing—Access and Diagnosis, and Direct-to-Consumer vs. Clinical Testing”
Tuesday, May 24, 2022, 2:00 – 3:00 p.m. ET

Watch the recording

Presenter: Sajel Kana, MD, FAAP, FACMG and physician clinical reviewer, Magellan Healthcare

Presenter: Gillian Hooker, PhD, ScM, LCGC, chief scientific officer, Concert Genetics

With more than 175,000 orderable testing products available today [1], genetic testing has become increasingly complex. Direct-to-consumer testing has also expanded the number of people who are able to get genetic testing—by the start of 2019, more than 26 million people had taken an at-home DNA test.[2] The proliferation of genetic tests and options available has ushered in new challenges, including barriers to access.

If you missed the live event, view the recording to hear Magellan Healthcare’s Dr. Sajel Kana, board-certified clinical geneticist, and Concert Genetics’ Dr. Gillian Hooker, board-certified genetic counselor and molecular biologist, address the genetic testing landscape, access to genetic testing, and the differences between direct-to-consumer and clinical genetic tests.

Watch the recording

[1] Concert Genetics, 2022

[2] https://www.geneticsandsociety.org